// App-Quantinova.ai

3562 : Dual Inhibition of JAK/STAT and MAPK Pathways Results in Synergistic Cell Killing of JAK-Mutated Pediatric Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Keith CS Sia

Principal Investigators

  • Lauryn Bracken

  • Hernan Carol

  • Kathryn Evans

  • Raushan Kurmasheva

  • Peter J. Houghton

  • Malcolm A. Smith

  • Richard B. Lock

Medical Centers

  • Children's Cancer Institute Australia for Medical Research, University of New South Wales, Randwick, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Myeloid neoplasms

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • Dual specificity mitogen-activated protein kinase kinase 1

  • Breakpoint Cluster Region

  • Phosphorylated mitogen-activated protein kinase 1

  • Phosphorylated mitogen-activated protein kinase 3

  • Phosphorylated signal transducer and activator of transcription 1

  • Phosphorylated-AKT

Drug/Treatment

  • selumetinib

  • AZD-1480

  • AZD-6244

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved